Retrospective analysis shows bevacizumab alternating chemotherapy enhances survival in patients with high-grade glioma, indicating promising implications for treatment.
Key Points
The bevacizumab alternating chemotherapy regimen significantly improves overall survival in grade 4 gliomas, achieving 29 months versus 19 months.
Median postrecurrence survival for grade 4 glioma patients on the BAC regimen was 16 months compared to 10 months for those on bevacizumab alone.
Data from 95 adult patients were analyzed, highlighting the potential benefits of the BAC approach specifically for IDH-wild-type glioma cases.
The ongoing evaluation of the BAC regimen in future randomized studies is crucial for confirming its advantages and addressing retrospective analysis limitations.